Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 8fludarabine 5Specimen Handling 5Standard of Care 4trametinib 3Practice Guidelines as Topic 3Mycophenolic Acid 3Magnetic Resonance Spectroscopy 3GSK2636771 3Biopsy 3venetoclax 2talquetamab 2osimertinib 2dabrafenib 2capivasertib 2binimetinib 2X-Rays 2Whole-Body Irradiation 2Thiotepa 2Tacrolimus 2Surveys and Questionnaires 2Patient Navigation 2Nivolumab 2Methods 2Mesna 2Melphalan 2Filgrastim 2Educational Status 2Early Intervention, Educational 2Crizotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Amides × 30 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡